International Journal of Women's Health Care(IJWHC)
ISSN: 2573-9506 | DOI: 10.33140/IJWHC
Impact Factor: 1.011
Dan Li
The Second Department of Thoracic Medical Oncology, The Second Hospital, of Dalian Medical University, Dalian, Liaoning, China
Publications
-
Research Article
A Clinical Research of Ceritinib Treating Patients with ALK-Positive Advanced Non-small Cell Lung Cancer with Brain Metastasis
Author(s): Saiqiong Cui*, Xin Liu, Dan Li, Dafu Yang and Zhaoxia Dai*
Objective: As a second-generation oral anaplastic lymphoma kinase (ALK) inhibitor, ceritinib was recommended as posterior line therapy in patients with crizotinib resistance or intolerance. While in the real world, the clinical efficacy and safety of ceritinib, 450mg/d, taken with a low-fat meal in crizotinib resistant patients, especially with brain metastases, are still to be further investigated. Methods: This retrospective analysis was conducted on patients with ALK- positive advanced non-small cell lung cancer (NSCLC) between May 2017 and December 2020 in our hospital, who were crizotinib resistant or intolerant. The aim was to analyze the clinical efficacy and safety of ceritinib as posterior line therapy in patients, especially in those with brain metastases, and to further explore the efficacy against rare fusion of ALK and the optio.. Read More»